Biomarkers in Prostate-Specific Membrane Antigen Theranostics

Theranostics of prostate cancer (PC) represents a growing area of development of imaging agents and targeted radionuclide therapeutics against a major target, prostate specific membrane antigen (PSMA). In view of the encouraging efficacy from the use of (177)Lu and other radionuclides in metastatic...

Descripción completa

Detalles Bibliográficos
Autores principales: Vlachostergios, Panagiotis J., Zachos, Ioannis, Tzortzis, Vassilios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235046/
https://www.ncbi.nlm.nih.gov/pubmed/34207069
http://dx.doi.org/10.3390/diagnostics11061108
_version_ 1783714224976953344
author Vlachostergios, Panagiotis J.
Zachos, Ioannis
Tzortzis, Vassilios
author_facet Vlachostergios, Panagiotis J.
Zachos, Ioannis
Tzortzis, Vassilios
author_sort Vlachostergios, Panagiotis J.
collection PubMed
description Theranostics of prostate cancer (PC) represents a growing area of development of imaging agents and targeted radionuclide therapeutics against a major target, prostate specific membrane antigen (PSMA). In view of the encouraging efficacy from the use of (177)Lu and other radionuclides in metastatic castration-resistant prostate cancer (mCRPC), it is becoming increasingly important to identify surrogate markers that can help predict which patients are more likely to respond and experience improved survival. This review discusses potential predictors of efficacy of PSMA-targeted radionuclide therapies (TRT) segregated in three major categories: imaging, clinical and molecular.
format Online
Article
Text
id pubmed-8235046
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82350462021-06-27 Biomarkers in Prostate-Specific Membrane Antigen Theranostics Vlachostergios, Panagiotis J. Zachos, Ioannis Tzortzis, Vassilios Diagnostics (Basel) Review Theranostics of prostate cancer (PC) represents a growing area of development of imaging agents and targeted radionuclide therapeutics against a major target, prostate specific membrane antigen (PSMA). In view of the encouraging efficacy from the use of (177)Lu and other radionuclides in metastatic castration-resistant prostate cancer (mCRPC), it is becoming increasingly important to identify surrogate markers that can help predict which patients are more likely to respond and experience improved survival. This review discusses potential predictors of efficacy of PSMA-targeted radionuclide therapies (TRT) segregated in three major categories: imaging, clinical and molecular. MDPI 2021-06-18 /pmc/articles/PMC8235046/ /pubmed/34207069 http://dx.doi.org/10.3390/diagnostics11061108 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Vlachostergios, Panagiotis J.
Zachos, Ioannis
Tzortzis, Vassilios
Biomarkers in Prostate-Specific Membrane Antigen Theranostics
title Biomarkers in Prostate-Specific Membrane Antigen Theranostics
title_full Biomarkers in Prostate-Specific Membrane Antigen Theranostics
title_fullStr Biomarkers in Prostate-Specific Membrane Antigen Theranostics
title_full_unstemmed Biomarkers in Prostate-Specific Membrane Antigen Theranostics
title_short Biomarkers in Prostate-Specific Membrane Antigen Theranostics
title_sort biomarkers in prostate-specific membrane antigen theranostics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235046/
https://www.ncbi.nlm.nih.gov/pubmed/34207069
http://dx.doi.org/10.3390/diagnostics11061108
work_keys_str_mv AT vlachostergiospanagiotisj biomarkersinprostatespecificmembraneantigentheranostics
AT zachosioannis biomarkersinprostatespecificmembraneantigentheranostics
AT tzortzisvassilios biomarkersinprostatespecificmembraneantigentheranostics

Ejemplares similares